Palvella Therapeutics (NASDAQ:PVLA) Given Consensus Rating of “Buy” by Brokerages

Palvella Therapeutics (NASDAQ:PVLA) has received an average recommendation of “Buy” from the seven analysts that are currently covering the firm, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $43.50.

PVLA has been the topic of a number of research reports. Cantor Fitzgerald started coverage on shares of Palvella Therapeutics in a research note on Wednesday, December 18th. They issued an “overweight” rating on the stock. Canaccord Genuity Group restated a “buy” rating and set a $39.00 price objective on shares of Palvella Therapeutics in a research report on Wednesday, February 26th. TD Cowen began coverage on Palvella Therapeutics in a research report on Wednesday, February 5th. They set a “buy” rating and a $44.00 price target for the company. HC Wainwright restated a “buy” rating and issued a $38.00 price objective on shares of Palvella Therapeutics in a research report on Tuesday, February 11th. Finally, Scotiabank began coverage on Palvella Therapeutics in a research report on Friday, March 7th. They set a “sector outperform” rating and a $50.00 price objective for the company.

Palvella Therapeutics Stock Up 1.2 %

NASDAQ PVLA opened at $28.10 on Tuesday. The company has a 50 day moving average price of $20.24. The stock has a market cap of $315.31 million, a P/E ratio of -2.32 and a beta of 0.54. Palvella Therapeutics has a 1-year low of $6.20 and a 1-year high of $29.27.

Institutional Investors Weigh In On Palvella Therapeutics

Several institutional investors have recently bought and sold shares of PVLA. Suvretta Capital Management LLC acquired a new stake in Palvella Therapeutics in the 4th quarter valued at $8,574,000. BVF Inc. IL acquired a new stake in Palvella Therapeutics in the fourth quarter valued at approximately $8,359,000. Samsara BioCapital LLC acquired a new position in shares of Palvella Therapeutics during the fourth quarter worth $8,154,000. Frazier Life Sciences Management L.P. acquired a new stake in Palvella Therapeutics during the 4th quarter valued at $7,847,000. Finally, Adams Street Partners LLC purchased a new stake in Palvella Therapeutics during the 4th quarter worth $4,916,000. 40.11% of the stock is currently owned by hedge funds and other institutional investors.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.